JP Morgan Healthcare Conference

11 January 2017

Eun Chul Huh, Ph.D., President

GREEN CROSS

1

This presentation may contain forward-looking statements. Forward-looking statements give the

Company’s current expectations or forecasts of future events

The Company cautions investors that a number of important factors, including those in this document,

could cause actual results to differ materially from those expressed or implied in any forward-looking

statement. Nothing in this document should be constructed as a profit forecast.

Other than in accordance with its legal or regulatory obligations, the Company undertakes no

obligation to update any forward-looking statements, whether as a result of new information, future

events or otherwise.

Forward-Looking Statements

2

A Leading Biopharma Company in Korea

Overview

FinancialHighlights

Founded in 1967 and listed on KRX in 1978

The largest plasma products manufacturer in Asia

Leading Flu Vx supplier in Korea and pooled procurement by the PAHO

2015 marked as the 43rd consecutive profitable year

$0.5B Investment for Plasma and Vx Businesses for the past 5 years

2015 Sales No.3 in Korea

3

80%

20%

Green Cross Others

Domestic M/S

50% 50%

Green Cross Others

Plasma

Flu Vx

No.1

No.1

926

775

998

858

1,164

628

742

572 524 541

2015 2016.Q3

Green Cross Yuhan Hanmi Daewoong CKD

Unit : M USD

Sales

No.2

4

Green Cross Position in Korea

5

3 Launches

11 Submissions

6 Approvals

GC Flu Quadrivalent in Korea

The first and only locally produced H5N1 AI vaccine

The first and only locally produced Td vaccine

GC Flu Quadrivalent(single) prequalified by the WHO

IVIG SN 10% Ph-III IND (Canada)

IVIG SN 10% BLA (Korea)

GreenGene-F Ph-III IND (China)

Key Milestones in 2016

6

2015 2014 2013 2012

Sales 926 862 785 717

Operating Profit 81 86 70 66

Net Profit 85 77 64 49

R&D Expenditure(% of Sales)

87(9.4%)

68(7.9%)

63(8.0%)

61(8.5%)

*Unit : million USD, consolidated

Expect for 2016, to reach double-digit revenue growth with increasing the R&D investment

Financial Performance

7

13 Launches

11 Submissions

10 Approvals

IVIG SN 10% (KR)

Adult Td vaccine

IVIG SN 5% BLA Re-submission (US)

IVIG SN 10% IND for Ph-III (US)

HBIG-gene_Liver Transplantation_Ph-III IND (Korea)

EGFR mAb_Gastric & Colon Cancer Ph-1b/2a IND (Korea)

GC Flu Quadrivalent (multi) prequalified by the WHO

Expected Key Milestones in 2017

Sustain Local Leadershipin Plasma & Vaccine

8

Building StrongFoundation

Operational Excellencewith Biologics

1970s 1990s

First BiologicsBusiness in Korea

Global Scale Operation & Innovative Medicines

2020s

SustainableDelivery and Growth

2010s

Expansion toEmerging Market

Delivering onReturn to Growth

On Track for Long Term Growth

70%

30%

1970`s 1980`s 1990`s 2000`s 2010`s 2020`s

Vaccines

Specialty

Sustain LocalLeadership

Build CompetitiveGlobal Position

Local Emerging InternationalPlasma

80%

20%90%

10%

Local International

2011`

2016`

Substantial Growth Potential

2020`(E)

9

Strategic Outlook

Plasma Business: STRATEGIC ROADMAP to create compelling integration

Flu Vaccine Business: NEW OPERATIONAL MODEL to drive focus

What’s Next in R&D : SUSTAINABLE INNOVATION poised for long term value

1

2

3

10

3 PRIORITIES

Plasma Business: STRATEGIC ROADMAP to create compelling integration

Flu Vaccine Business: NEW OPERATIONAL MODEL to drive focus

What’s Next in R&D : SUSTAINABLE INNOVATION poised for long term value

1

2

3

11

3 PRIORITIES

0.4 0.40.5

0.60.7

0.80.9

1.01.1

1.6 1.6

2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020

Production Capa.

Sourcing

CANADA

1.0 Mℓ

1.7 Mℓ

2.7 Mℓ

Sourcing

KOREA + CHINA KOREA ×2

30 Plasma collection centersworldwide

Production3 Manufacturing PlantsIn 3 Countries

Commercial

12

Portfolio

Alb.IVIGFⅧ+By Products

Upgrade US, CanadaIVIGAlb.

16 Products KORChinaEmerging

Extra US, CanadaPCCFibrinogen

Building a durable and more profitable business With principal products

Branch office in IndiaWholesaler in CHINA

Sales Company in US (E)

EmergingCHINA

KOREA USCANADA

Toll Manufacturing Services in Canada

Local leadershipIn Plasma

1970s

2020s

Plasma Business Strategic Roadmap

Sourcing

30 by 2020 in US30 Plasma collection centers worldwide

San Bernardino

Calexico

Laredo

Twin Falls

Eagle Pass

Pullman

San Antonio

Leonvalley

2009 Established GCAM

San Bernardino

Calexico

Laredo

Eagle Pass

Pullman

Twinfalls

San Antonio

Leonvalley

+ 20 Centers

2013

2014

2015

2020

13

Extensive Investment in Plasma Collection

Production

3 Manufacturing Plants in 3 Countries

Location : O`Chang in KoreaCapa. : 0.7 Mℓ + 0.7 Mℓ (2017)

Location : Anhui in ChinaCapa. : 0.3 Mℓ

Location : Quebec in CanadaCapa. : 1.0 Mℓ (2019)

14

Extensive Investment in Production Sites

Global Plasma Market[Unit: $ M]

0

4,000

8,000

12,000

16,000

'14 '15 '16E '18E '20E '22E '24E

US IVIG Market

13.2

10.6

0

1,000

2,000

3,000

4,000

5,000

'14 '15 '16E '18E '20E '22E '24E

China Albumin Market

Reference: Marketing Research Bureau, A.T. Kearney Analysis 2014

[Unit: $ M]

0

5,000

10,000

15,000

20,000

25,000

30,000

'12 '14 '16E '18E '20E 22E 24E

CAGR 6% CAGR 10%

CAGR 12%

15

Commercial

CHINA - High demand of Albumin (CAGR 12%)

US - The world`s largest IVIG Market (CAGR 10%)

CHINA

CANADA

US

KOREA

Marketing IVIG, Alb.in more than 30 countries

Local leadershipIn Plasma since 1970

2012 Wholesaler in CHINA

2017 Sales Company in US (E)

2015 Toll Manufacturing Servicesto H.Q CANADA

2015 MKT office in India

Dynamic Market Place

Broaden Out PortfolioSourceOptimization

“Each new productout of 1 Liter willincrementallyimprove profit”

16

Cost

Profit

KOR Emerging CAD CHN US

Albumin

IVIG

Specialty Products

1.0 Mℓ[Fractionation] 2.7 Mℓ

2016 2020

Profit Fib.

IVIG

Albumin

IVIG,Alb.PCC

1970s~ 2010s 2020s~

Alb. IVIGSpecialty Products

Upgrade

PCC

Fibrinogen

GreenⅧ-U

USChina US

US

IVIGAlb.

16 Products

Plasma R&D Roadmap

17

1

Sourcing

3

Commercial

2

Production

CANADAUS CHINAKOREA

IVIGAlbumin

IVIGAlbumin

IVIGBy-Products

1.0M liters/ year

0.3M liters/ year

7 Plasma Centers

Héma Québec&

CanadianBlood Service

8 Plasma Centers

30 by 2020 10 by 2020

IVIGAlbumin

By-Products

1.3M liters/ year

KoreaRed Cross

Integrate Each Local Operation into Global Plasma Business

CHINA

CANADA

Sales

Sourcing

US

KOREA

Global Business via Integrating Key Resources

Plasma Business: STRATEGIC ROADMAP to create compelling integration

Flu Vaccine Business: NEW OPERATIONAL MODEL to drive focus

What’s Next in R&D : SUSTAINABLE INNOVATION poised for long term value

1

2

3

18

3 PRIORITIES

• Local leadership in seasonal influenza

vaccine

• More than 100 million doses of Green

Cross seasonal influenza vaccine

administered more than 30 countries

over the past 6 years

• Prequalified by WHO for global use

• Leading provider of influenza vaccine

to pooled procurement of PAHO

☞ Geographical Expansion

: Strength in Public: The largest Supplier for PAHO

Step 1) Mitigate Seasonality

PAHO

192011 2012 2013 2014 2015 2016

S/H N/H

Flu Vx Sales Portion

50%

Unit : dose

New Operational Model for Flu Vaccine

• Local leadership in seasonal influenza

vaccine

• More than 100 million doses of Green

Cross seasonal influenza vaccine

administered more than 30 countries

over the past 6 years

• Prequalified by WHO for global use

• Leading provider of influenza vaccine

to pooled procurement of PAHO

☞ Geographical Expansion

: Expansion to US Market with GC FLU™(QIV)

Step 2) Implement Economies of scale

US

KOREA

20

Business Expansion with Potential Growth

Influenza Vx

N/H : Local

S/H : PAHO

USStep 1)

Step 2)

Mitigate Seasonality

Implement Economies of scale

• Local leadership in seasonal influenza

vaccine

• More than 100 million doses of Green

Cross seasonal influenza vaccine

administered more than 30 countries

over the past 6 years

• Prequalified by WHO for global use

• Leading provider of influenza vaccine

to pooled procurement of PAHO

☞ Geographical Expansion ‘09 ‘11 ‘13 ‘15 ‘17 ‘19 ‘21

Multi & SingleQuadrIvalent VaccineWHO PQ

High-DoseEgg basedWHO PQ

TIV QIVQIV-HD

Thimerosal reduction

QIV-TR

QIV USUS

Pre-IND (Ph 3)

21

Business Expansion with Potential Growth

Plasma Business: STRATEGIC ROADMAP to create compelling integration

Flu Vaccine Business: NEW OPERATIONAL MODEL to drive focus

What’s Next in R&D : SUSTAINABLE INNOVATION poised for long term value

1

2

3

22

3 PRIORITIES

Maintain commitment to extracting

maximum value from existing products

Sustainable Growth & Global Expansion

Concentrate on developing innovative products that align

with our technical and commercial capabilities

R&D for Next-Generation Therapy

23

Poised for Long Term Value

24

Pre-Clinical Phase I/II Phase III

Plasma

Vaccine

GC5101BIVIG SN 10%(US)

GC5101FIVIG 5% (US, Child)

GC3110BQIV (multi)

MG1111Varicella Vx

GC3110GQIV (US)

GC5112AFibrinogen

GC5113AAlbumin 25%(CA)

GC3110CQIV (Multi-TR)

GC5111AGreenVIII-U

GC5122AIg-CAP

GC3114AQIV-HD

GC3110DQIV (child)

GC3111ATdap Vx

GC1109Anthrax Vx

GC3104ADTaP Vx

MG1120AVZV(subunit)

GC5121APCC

Pipelines

25

Pre-Clinical Phase I/II Phase III

Plasma

Vaccine

GC5101BIVIG SN 10%(US)

GC5101FIVIG 5% (US, Child)

GC3110BQIV (multi)

MG1111Varicella Vx

GC3110GQIV (US)

GC5112AFibrinogen

GC5113AAlbumin 25%(CA)

GC3110CQIV (Multi-TR)

GC5111AGreenVIII-U

GC5122AIg-CAP

GC3114AQIV-HD

GC3110DQIV (child)

GC3111ATdap Vx

GC1109Anthrax Vx

GC3104ADTaP Vx

MG1120AVZV(subunit)

GC5121APCC

Discovery

MG1124AT de-repressor

MG1122AT engager I

MG1126AT engager II

MG1127ANew target

MG1130ANew target

MG9105ANew target

MG9108ANew target

Recombinant & Others

GC1124AHunterase (SC)

MG1113ATFPI mAb

GC9104AADC

MG1121ALAFATE

GC1123AHunterase (ICV)

GC1102BHepabig-gene (CHB)

GC1118AEGFR mAb

MGAH22Her2 mAb

GC1111BHunterase(US)

GC1101GGreenGene F(2000IU)

GC1102Hepabig-gene (LT)

GC1101DGreenGene F(China)

GC1111FHunterase (P3)

Pipelines

Green VIIIGreen Mono

GreenGene FLong-Acting FVIII

TFPI Ab

Plasma Derived FVIII Recombinant Human FVIIIApproved in Korea in 2011Clinical Trial Phase 3 in China

Innovative Approach

Safety, Patients’ Convenience and Future

Dedicated to Hemophilia

26

Quest for Innovation in Hematology

rFVIII3~4 per week

Long-Acting2~3 per week

Next Generation1 per week

Innovative Therapy1 per＞2 weeks

27

Robust FVIII Portfolio

Increasing the FVIII stability

Minimizing the immunogenicity

Similar form as the naïve FVIIIa

PEGylation

Single chain FVIII

D’D3 domain of VWF

PEGylation in the B domain

Demand for Protein design Solution

Cleavable linker between FVIII andD’D3 domain

B-domain can cleave at bleedingcondition by thrombin

28

Escaping from FVIII and vWF clearance

Next Generation FVIII Program

29

Next Generation FVIII Program Highlights

*** p<0.001

***

30

Innovative Hematology Program Highlights

Plasma-Derived Products Recombinant Protein Monoclonal AntibodyWorld 2nd drug for Hunter Syndrome (MPS II)

Recombinant Factor VIII

Ph.1 & Ph2. for

*LT & **CHB

Ph.1 for colorectal

& gastric cancer

*LT : Prevention of HBV recurrence following Transplantation

**CHB : Chronic Hepatitis B (CHB)

Green Eight™(Plasma-derived Factor VIII)

Hepabig™(Plasma-derived Hepatitis B IgG)

GreenGene F ™(Recombinant Factor VIII)

Hunteraseanti-EGFR mAb

Hepabig-Gene

anti-TFPI mAb

31

Accumulated technologies and process of rec-Proteins

New Focus Area : Immuno-Oncology

Innovative Platforms in the Field of Immunology & Protein engineering

32

Expertise in Innovative Platform

33

Ab

CellImmuneCell-LCTM

Autologous T cellPh 3. completed in HCC

ImmuneCell-LCTM

Autologous T cellPh 2~3. other cancers (2013~)

External

MG4101Allogenic NK cell

Ph 1. completed (2013)

MG4101Allogenic NK cell

Ph 2. *HCC

*HCC : Hepatocellular Carcinoma

~2014 2015 2016 2017~

GC1102HBIG-Gene

Ph 2. LT

GC1102HBIG-GenePh 1. CHB

GC1102HBIG-Gene

Ph 1. LT_completed (2014)

GC1118AAnti EGFR Antibody

Ph-1 completed (2015)

GC1118AAnti EGFR Antibody

Ph 1b/2a Colorectal & Gastric Cancer

MGAH22Anti Her2 antibodyPh 3. Breast Cancer

Collaboration with Magrogenics

External

Experienced in Cell & Ab Therapeutics

: Focus on Early Discovery & Partnership

Key SuccessFactors

•Longstanding Capabilities in the Complex Field of

Hematology and Immunology

•Extensive Expertise in Antibody with Innovative

Platform

•Foundation of Existing Cell Therapy Capabilities

Implement a Risk-balanced, Capital-efficient Strategy

•Totally new targets

•Platform Technologies

•Partnership

Strong Competency

Green CrossPD1

PD-L1

TIGIT

CEACAM-1

BTLA

VISTA

HLA-G

New Targets

EGFR

CD3

HER 3

Mesothelin

GPC-3

TIGIT

BCMA

New Targets

How We Approach Immuno-Oncology

35

‘Transform’

Invest for long-term value

Simplify the global Portfolio

Reinforce pipeline through

Business Development

Continue to build scale in priority business

Capture margin improvement

AccelerateGrowth

CurrentBusiness

GlobalExpansion

Innovation

WHAT TO EXPECT

Thank you

36